Document is current

Article History

Accepted: 12 March 2025

First Online: 25 March 2025

Declarations

:

: None.

: None to declare for Kayla Mashoudy. None to declare for Ana Tomlinson. None to declare for Sarah Kim. None to declare for Vanya Shivashankar. None to declare for Michelle Fletcher. Conflicts of interest for Gil Yosipovitch: Abbvie, Arcutis, Almiral, Amgen, Celldex, Escient Health, Eli Lilly, Galderma, LEO Pharma, Merck, Novartis, Pfizer, Pierre Fabre, Regeneron Pharmaceuticals, Inc., Sanofi, Vifor, GSK—advisory board member; Eli Lilly, LEO Pharma, Novartis, Pfizer, Galderma, Escient, Sanofi, Regeneron, Sanofi Celldex, Pfizer– grants/research funding; Regeneron Pharmaceuticals, Inc., Sanofi—Galderma investigator. Gil Yosipovitch is an Editorial Board member of the American Journal of Clinical Dermatology. Gil Yosipovitch was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

: Kayla Mashoudy: conceptualization, methodology, and writing—original and final draft preparation. Ana Tomlinson: material preparation and writing—original draft preparation. Sarah Kim: material preparation, writing—original draft preparation. Vanya Shivashankar: material preparation and writing—original draft preparation. Gil Yosipovitch: supervision, writing, and manuscript review. Michelle Fletcher: supervision, writing, and manuscript review. All authors read and approved the final manuscript.